Quick Answer
Amphastar Pharmaceuticals, Inc. reported Net Income Loss of $98.09 million for the year ending 2025.
- Amphastar Pharmaceuticals, Inc. showed a decrease of -38.5% in Net Income Loss from 2024 to 2025.
- This data is from Amphastar Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$665.0 thousand | Q2 2015: -$6.65 million | Q3 2015: -$3.01 million | Q4 2015: $7.53 million | Q1 2016: $2.49 million | Q2 2016: $6.90 million | Q3 2016: $3.89 million | Q4 2016: -$2.74 million | Q1 2017: $893.0 thousand | Q2 2017: $1.97 million | Q3 2017: $99.0 thousand | Q4 2017: $1.47 million | Q1 2018: -$7.14 million | Q2 2018: -$2.85 million | Q3 2018: $2.39 million | Q4 2018: $1.87 million | Q1 2019: $868.0 thousand | Q2 2019: $47.79 million | Q3 2019: $1.31 million | Q4 2019: -$1.03 million | Q1 2020: $3.95 million | Q2 2020: -$192.0 thousand | Q3 2020: $3.92 million | Q1 2021: $5.04 million | Q2 2021: $7.77 million | Q3 2021: $29.55 million | Q1 2022: $24.25 million | Q2 2022: $17.35 million | Q3 2022: $15.87 million | Q1 2023: $26.03 million | Q2 2023: $26.12 million | Q3 2023: $49.22 million | Q1 2024: $43.18 million | Q2 2024: $37.95 million | Q3 2024: $40.43 million | Q1 2025: $25.29 million | Q2 2025: $31.03 million | Q3 2025: $17.35 million.
- Over the full 14 years of available data (2012 to 2025), Amphastar Pharmaceuticals, Inc.'s Net Income Loss has grown by 442.1%.
- Historical annual values: Fiscal year 2025: $98.09 million | Fiscal year 2024: $159.52 million | Fiscal year 2023: $137.55 million | Fiscal year 2022: $91.39 million | Fiscal year 2021: $62.12 million | Fiscal year 2020: $1.40 million | Fiscal year 2019: $48.94 million | Fiscal year 2018: -$5.74 million | Fiscal year 2017: $3.65 million | Fiscal year 2016: $9.82 million | Fiscal year 2015: -$2.79 million | Fiscal year 2014: -$10.70 million | Fiscal year 2013: $11.86 million | Fiscal year 2012: $18.09 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: